As a potential target for cancer treatment, the current drug development efforts against STAT3 involve direct inhibition using peptides, small molecules, and decoy oligonucleotides (70–73), or indirect inhibition through blocking upstream signaling pathways such as the IL-6 and JAK2 pathways (74, 75). Here, STAT3 is linked to cancer.